Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions
Open Access
- 18 July 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3749-3759
Abstract
The National Heart, Lung, and Blood Institute–funded National MDS Natural History Study (NCT02775383) is a prospective cohort study enrolling patients with cytopenia with suspected myelodysplastic syndromes (MDS) to evaluate factors associated with disease. Here, we sequenced 53 genes in bone marrow samples harvested from 1298 patients diagnosed with myeloid malignancy, including MDS and non-MDS myeloid malignancy or alternative marrow conditions with cytopenia based on concordance between independent histopathologic reviews (local, centralized, and tertiary to adjudicate disagreements when needed). We developed a novel 2-stage diagnostic classifier based on mutational profiles in 18 of 53 sequenced genes that were sufficient to best predict a diagnosis of myeloid malignancy and among those with a predicted myeloid malignancy, predict whether they had MDS. The classifier achieved a positive predictive value (PPV) of 0.84 and negative predictive value (NPV) of 0.8 with an area under the receiver operating characteristic curve (AUROC) of 0.85 when classifying patients as having myeloid vs no myeloid malignancy based on variant allele frequencies (VAFs) in 17 genes and a PPV of 0.71 and NPV of 0.64 with an AUROC of 0.73 when classifying patients as having MDS vs non-MDS malignancy based on VAFs in 10 genes. We next assessed how this approach could complement histopathology to improve diagnostic accuracy. For 99 of 139 (71%) patients (PPV of 0.83 and NPV of 0.65) with local and centralized histopathologic disagreement in myeloid vs no myeloid malignancy, the classifier-predicted diagnosis agreed with the tertiary pathology review (considered the internal gold standard).Keywords
This publication has 27 references indexed in Scilit:
- Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionBlood, 2015
- MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significanceBlood, 2015
- The Challenging World of Cytopenias: Distinguishing Myelodysplastic Syndromes From Other Disorders of Marrow FailureThe Oncologist, 2014
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromesHaematologica, 2012
- Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classificationAnnals of Hematology, 2012
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donorsHaematologica, 2011
- Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centersBlood, 2011
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009